Breaking News Instant updates and real-time market news.

VRTX

Vertex

$87.77

0.43 (0.49%)

, ALIOF

Actelion

$184.01

30.46 (19.84%)

09:52
11/28/16
11/28
09:52
11/28/16
09:52

Vertex, BioMarin rumored as takeover targets, Betaville's Harrington says

In a new interview with Tip TV Finance, Betaville's Ben Harrington discussed rumors that Vertex (VRTX) and BioMarin (BMRN) could be takeover targets. Harrington also discussed rumors regarding Actelion (ALIOF) and the price it may seek from Johnson & Johnson (JNJ). In multiple previous interviews with Tip TV, and once again in his new interview, Harrington discussed rumors that Roche (RHHBY) was considering revisiting a bid for Illumina (ILMN). Reference Link

VRTX

Vertex

$87.77

0.43 (0.49%)

ALIOF

Actelion

$184.01

30.46 (19.84%)

JNJ

Johnson & Johnson

$113.84

-0.2903 (-0.25%)

ILMN

Illumina

$135.19

0.76 (0.57%)

RHHBY

Roche

$28.02

0.6 (2.19%)

BMRN

BioMarin

$89.00

0.9 (1.02%)

  • 29

    Nov

  • 02

    Dec

  • 03

    Dec

  • 07

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

VRTX Vertex
$87.77

0.43 (0.49%)

11/14/16
PIPR
11/14/16
NO CHANGE
PIPR
Piper sees Biotech rally continuing into 2017, lays out five to own
Piper Jaffray analyst Edward Tenthoff expects the rally in Biotechs, following "the trifecta" of a Trump Presidential election, Republican Congress sweep and defeat of Prop 61 in California, to continue into 2017. He recommends focusing on shares of Vertex (VRTX), Regeneron (REGN), Alnylam (ALNY), Exelixis (EXEL) and OncoMed (OMED). Tenthoff has a Neutral rating on Regeneron and Overweight ratings on the other four names.
11/17/16
JANY
11/17/16
INITIATION
JANY
Neutral
Vertex initiated with a Neutral at Janney Capital
11/18/16
JANY
11/18/16
INITIATION
Target $98
JANY
Neutral
Vertex initiated with a Neutral at Janney Capital
Janney Capital analyst Debjit Chattopadhyay initiated Vertex with a Neutral and a $98 price target citing valuation premium.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.
ALIOF Actelion
$184.01

30.46 (19.84%)

11/28/16
WELS
11/28/16
NO CHANGE
WELS
Actelion could be acquired for $215 per share, says Wells Fargo
After Johnson & Johnson (JNJ) said that it's in preliminary talks about a deal with Actelion (ALIOF), Wells Fargo estimates that J&J could buy Actelion for $215 per share. The firm thinks that other bidders could emerge for Actelion. It estimates that the deal could be accretive to J&J's EPS by about 5%. Wells keeps an Outperform rating on J&J.
JNJ Johnson & Johnson
$113.84

-0.2903 (-0.25%)

10/19/16
UBSW
10/19/16
NO CHANGE
Target $144
UBSW
Buy
Johnson & Johnson has potential upside from expanding pipeline, says UBS
UBS analyst Matt Miksic noted Johnson & Johnson delivered a solid quarter and said he believes there is upside to his Buy thesis. The analyst cited the company's expanding pipeline, capital allocation strategy, and contracting across its broad portfolio and patient assistance programs is expected to help mitigate pressure from biosimilar competition. Miksic reiterated his Buy rating and raised his price target to $144 from $137 on Johnson & Johnson shares.
10/19/16
LEER
10/19/16
NO CHANGE
Target $140
LEER
Outperform
Johnson & Johnson should be bought on weakness, says Leerink
Leerink analyst Danielle Antalffy believes the recent selloff in Johnson & Johnson's shares was overdone and would recommend buying on weakness. The analyst views the company as well-equipped to manage the inevitable Remicade headwind and continues to believe Johnson & Johnson can drive improving top-line growth in 2017. She reiterates an Outperform rating and $140 price target on the shares.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Johnson & Johnson should be bought on recent weakness, says RBC Capital
After meeting with J&J's VP, Investor Relations, RBC Capital analyst Glenn Novarro says that the company's Q3 pharma results indicate that the growth of its major drugs can more than offset any declines in Remicade sales next year. The analyst quotes J&J as saying that it has not been using price hikes to increase its sales, and he thinks that the company's diverse business model will allow it to avoid being hurt by any regulatory pressures. He is upbeat on the company's efforts to increase its margins and notes that its medical device results have improved. Novarro keeps a $133 price target and an Outperform rating on the shares.
ILMN Illumina
$135.19

0.76 (0.57%)

10/11/16
10/11/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Comerica (CMA) downgraded to Market Perform from Outperform at FBR Capital with analyst Bob Ramsey citing valuation following the recent strength in the shares. 2. Charter downgraded to Neutral from Buy at MoffettNathanson with analyst Craig Moffett saying shares have risen sharply year-to-date, along with consensus estimates, and views shares as fairly valued. 3. BHP Billiton (BHP) downgraded to Neutral from Buy at UBS with the firm citing its expectations for lower iron ore and coal prices over the next six months. 4. Illumina (ILMN) downgraded to Sell from Neutral at Janney Capital and to Neutral from Buy at Citi. 5. KBR (KBR) downgraded to Sell from Neutral at Goldman with analyst Jerry Revich citing limited growth prospects due to outsized exposure to core LNG and greenfield ammonia capex cycles that are in the early stages of decline. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/11/16
JANY
10/11/16
DOWNGRADE
JANY
Sell
Illumina downgraded to Sell from Neutral at Janney Capital
11/10/16
LEER
11/10/16
INITIATION
Target $145
LEER
Market Perform
Illumina resumed with a Market Perform at Leerink
Leerink analyst Puneet Souda resumed coverage of Illumina with a Market Perform rating and $145 price target.
11/02/16
FANA
11/02/16
DOWNGRADE
Target $116
FANA
Underweight
Illumina downgraded to Underweight from Equal-Weight at First Analysis
First Analysis analyst Joseph Munda downgraded Illumina to Underweight saying the valuation is too high given management's "unconvincing arguments about the outlook," his concerns regarding overcapacity and a "continued lack of new products in the near-term pipeline." The analyst lowered his price target for the shares to $116 from $130 following Illumina's Q3 results.
RHHBY Roche
$28.02

0.6 (2.19%)

11/09/16
SBSH
11/09/16
NO CHANGE
SBSH
Citi sees Healthcare 'relief rally' after Trump win
Citi analyst Andrew Baum expects a "'relief rally" to drive near-term sector outperformance for names in the Healthcare space given the "inability of the Democrats to attain the Presidency, the House or Congress." Longer term, however, the analyst still sees "significant continued legislative risk" for pharma reimbursement. Baum prefers GlaxoSmithKline (GSK), AstraZeneca (AZN), Shire (SHPG) and Roche (RHHBY) among European majors and Bristol-Myers (BMY) and Eli Lilly (LLY) in the U.S.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
10/19/16
LEER
10/19/16
NO CHANGE
LEER
Roche Tecentriq approval increases competition, says Leerink
Leerink analyst Seamus Fernandez says that the FDA approval of Roche's (RHHBY) Tecentriq in second-line non-small cell lung cancer patients regardless of PD-L1 expression comes as no surprise given its previously reported overall survival advantage. Nonetheless, the analyst believes it creates new competition for Bristol-Myers' (BMY) Opdivo and Merck's (MRK) Keytruda in this setting.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
BMRN BioMarin
$89.00

0.9 (1.02%)

11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Biotech stocks should be bought on post-election decline, says RBC Capital
RBC Capital recommends buying biotech stocks today on weakness. The firm notes that stocks usually rebound after they drop due to political events that don't affect their fundamentals, and it believes that the decline in biotech stocks today is in that category. The firm says that President-elect Trump probably won't focus on drug prices or Medicare reform. It adds that biotech companies should benefit from the fact that Congress will stay in GOP hands and the apparent failure of California's Proposition 61 initiative. The firm identifies Celgene (CELG), Biogen (BIIB), Vertex (VRTX), BioMarin (BMRN), and Prothena (PRTA) as its favorite names in the sector.
11/07/16
11/07/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BioMarin (BMRN) downgraded to Neutral from Overweight at Piper Jaffray with analyst Joshua Schimmer saying he sees a "number of under-appreciated" risks ahead. 2. Akorn (AKRX) downgraded to Underperform from Buy at BofA/Merrill and to Hold from Buy at WallachBeth. 3. GoPro (GPRO) downgraded to Underperform from Neutral at BofA/Merrill. 4. L Brands (LB) downgraded to Underperform from Hold at Jefferies with analyst Randal Konik citing rising competition and pricing competition. 5. Xerox (XRX) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Brian Essex saying both the BPO and DocTech businesses are facing secular pressures and said the Conduent spinco will add $2B of net incremental leverage and faces headwinds in both growth and pricing and will need to focus on margin expansion to drive shareholder value. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, cllick here.
11/07/16
PIPR
11/07/16
UPGRADE
Target $335
PIPR
Overweight
Biogen upgraded to Overweight from Neutral at Piper Jaffray
In a research note partially titled "We Hope We Don't Regret This," Piper Jaffray analyst Joshua Schimmer upgraded Biogen (BIIB) to Overweight with an unchanged price target of $335. The company still has time to "get its act together to maximize the value of its SMA franchise, and stop being M&A disciplined/pipeline-undisciplined," Schimmer tells investors in a research note. He believes the valuation is "reasonable" for the Alzheimer's and SMA franchises as well as some "interesting" pipeline opportunities. Schimmer this morning also downgraded BioMarin (BMRN) to Neutral.

TODAY'S FREE FLY STORIES

FND

Floor & Decor Holdings

20:03
04/26/17
04/26
20:03
04/26/17
20:03
Syndicate
Floor & Decor Holdings 8.824M share IPO priced at $21.00 »

The deal priced above the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

SNE

Sony

$33.58

-0.07 (-0.21%)

, FOX

21st Century Fox

$30.05

0.16 (0.54%)

20:02
04/26/17
04/26
20:02
04/26/17
20:02
Periodicals
Sony narrows search for studio boss to Vinciquerra, WSJ says »

Former Fox (FOX) TV head…

SNE

Sony

$33.58

-0.07 (-0.21%)

FOX

21st Century Fox

$30.05

0.16 (0.54%)

FOXA

21st Century Fox

$30.74

0.13 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 10

    May

  • 24

    May

  • 25

    May

  • 15

    Jun

VZ

Verizon

$47.36

0.66 (1.41%)

19:57
04/26/17
04/26
19:57
04/26/17
19:57
Periodicals
Verizon go90 boss departs, Business Insider says »

Verizon go90 chief Chip…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

SSNLF

Samsung

19:45
04/26/17
04/26
19:45
04/26/17
19:45
Hot Stocks
Samsung sees FY17 earnings growth, cites health in memory, OLED »

"Moving on to the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

19:42
04/26/17
04/26
19:42
04/26/17
19:42
Hot Stocks
Samsung sees Q2 growth due to 'robust' memory performance, Galaxy S8 launch »

"Looking ahead to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSNLF

Samsung

19:40
04/26/17
04/26
19:40
04/26/17
19:40
Earnings
Samsung reports Q1 operating profit 9.9T won vs. 6.68T won last year »

Reports Q1 revenue 50.55T…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADM

Archer Daniels

$45.27

-0.31 (-0.68%)

19:36
04/26/17
04/26
19:36
04/26/17
19:36
Periodicals
Archer Daniels appoints new head of global trading desk, Reuters says »

Archer Daniels has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

FTI

TechnipFMC

$32.26

0.14 (0.44%)

19:35
04/26/17
04/26
19:35
04/26/17
19:35
Earnings
TechnipFMC reports Q1 adjusted EPS 71c, consensus 33c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

F

Ford

$11.60

0.12 (1.05%)

, GM

General Motors

$34.38

0.39 (1.15%)

19:29
04/26/17
04/26
19:29
04/26/17
19:29
Periodicals
Transportation, EPA chiefs to meet with major automakers, Reuters says »

Transportation Secretary…

F

Ford

$11.60

0.12 (1.05%)

GM

General Motors

$34.38

0.39 (1.15%)

TM

Toyota

$109.91

1.19 (1.09%)

VLKAY

Volkswagen

$32.13

-0.2 (-0.62%)

FCAU

Fiat Chrysler

$11.65

1.11 (10.53%)

DDAIF

Daimler AG

$74.57

-0.6001 (-0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 02

    May

CMCSA

Comcast

$38.79

0.3 (0.78%)

, CMCSK

Comcast

19:24
04/26/17
04/26
19:24
04/26/17
19:24
Hot Stocks
Comcast responds to FCC net neutrality news, says committed to open Internet »

Responding to FCC…

CMCSA

Comcast

$38.79

0.3 (0.78%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

PCH

Potlatch

$46.50

1.25 (2.76%)

19:18
04/26/17
04/26
19:18
04/26/17
19:18
Earnings
Potlatch reports Q1 EPS 41c, consensus 20c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

DBOEY

Deutsche Boerse

$9.59

-0.005 (-0.05%)

19:13
04/26/17
04/26
19:13
04/26/17
19:13
Hot Stocks
Deutsche Boerse says plans EUR 200M repurchase program »

Deutsche Boerse announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBLI

Cleveland BioLabs

$3.64

-0.11 (-2.93%)

19:03
04/26/17
04/26
19:03
04/26/17
19:03
Hot Stocks
Cleveland BioLabs names John Szydlo principal financial officer »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$30.62

-0.53 (-1.70%)

19:02
04/26/17
04/26
19:02
04/26/17
19:02
Hot Stocks
Suncor to repurchase up to C$2B of company's shares through NCIB »

Suncor announced plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

NBR

Nabors Industries

$11.74

-0.03 (-0.25%)

18:53
04/26/17
04/26
18:53
04/26/17
18:53
Earnings
Nabors Industries reports Q1 cont-op EPS with item (52c), consensus (35c) »

Reports Q1 revenue $563M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

RTN

Raytheon

$155.27

-0.74 (-0.47%)

18:40
04/26/17
04/26
18:40
04/26/17
18:40
Hot Stocks
Raytheon awarded $375M U.S. Air Force contract »

The U.S. Air Force…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

NOV

National Oilwell

$36.15

0.33 (0.92%)

18:38
04/26/17
04/26
18:38
04/26/17
18:38
Hot Stocks
National Oilwell reports Q1 book-to-bill of 41% for Rig Systems »

Backlog for capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

  • 01

    May

OIS

Oil States

$32.10

-0.3 (-0.93%)

18:36
04/26/17
04/26
18:36
04/26/17
18:36
Earnings
Oil States reports Q1 adjusted EPS (34c), consensus (27c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

PSA

Public Storage

$223.93

-1.61 (-0.71%)

18:35
04/26/17
04/26
18:35
04/26/17
18:35
Earnings
Public Storage reports Q1 core FFO $2.37, consensus $1.65 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 27

    Apr

NOV

National Oilwell

$36.15

0.33 (0.92%)

18:31
04/26/17
04/26
18:31
04/26/17
18:31
Earnings
National Oilwell reports Q1 adjusted EPS (17c), consensus (21c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 01

    May

  • 01

    May

PUB

People's Utah Bancorp

$27.55

-0.2 (-0.72%)

18:25
04/26/17
04/26
18:25
04/26/17
18:25
Hot Stocks
People's Utah Bancorp announces CEO succession in 2018 »

People's Utah…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 17

    May

BSFT

BroadSoft

$38.70

0.45 (1.18%)

18:17
04/26/17
04/26
18:17
04/26/17
18:17
Hot Stocks
BroadSoft announces agreement with Telstra for Australia communications »

BroadSoft announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

RJF

Raymond James

$75.74

0.55 (0.73%)

18:14
04/26/17
04/26
18:14
04/26/17
18:14
Earnings
Raymond James reports Q2 adjusted EPS $1.28, consensus $1.14 »

Reports Q2 GAAP EPS 77c.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCTT

Ultra Clean

$17.51

-0.2 (-1.13%)

, TER

Teradyne

$33.77

0.21 (0.63%)

18:14
04/26/17
04/26
18:14
04/26/17
18:14
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Ultra…

UCTT

Ultra Clean

$17.51

-0.2 (-1.13%)

TER

Teradyne

$33.77

0.21 (0.63%)

CRY

CryoLife

$16.75

0.5 (3.08%)

ALSN

Allison Transmission

$37.47

0.53 (1.43%)

MKSI

MKS Instruments

$75.35

0.95 (1.28%)

AXTI

AXT, Inc.

$6.15

-0.25 (-3.91%)

PYPL

PayPal

$44.41

-0.3 (-0.67%)

GGG

Graco

$99.80

1.45 (1.47%)

NOW

ServiceNow

$90.92

0.68 (0.75%)

XLNX

Xilinx

$59.99

-0.7 (-1.15%)

WPG

Washington Prime

$8.92

-0.09 (-1.00%)

MMLP

Martin Midstream Partners

$19.55

-0.15 (-0.76%)

CAVM

Cavium

$70.93

-0.31 (-0.44%)

WLL

Whiting Petroleum

$8.07

-0.22 (-2.65%)

ROG

Rogers Corporation

$92.47

3.23 (3.62%)

INTU

Intuit

$115.81

-3.27 (-2.75%)

WTW

Weight Watchers

$20.16

1.33 (7.06%)

HRB

H&R Block

$23.89

-0.35 (-1.44%)

MLNX

Mellanox

$50.90

-0.05 (-0.10%)

FFIV

F5 Networks

$137.30

-0.89 (-0.64%)

CMPR

Cimpress

$86.25

-0.07 (-0.08%)

CTXS

Citrix

$84.12

0.07 (0.08%)

NTGR

Netgear

$51.35

-1.55 (-2.93%)

ETH

Ethan Allen

$31.25

0.15 (0.48%)

AMGN

Amgen

$164.61

-0.09 (-0.05%)

KN

Knowles

$19.59

0.04 (0.20%)

BWLD

Buffalo Wild Wings

$162.40

-0.4 (-0.25%)

ORLY

O'Reilly Automotive

$265.07

1.11 (0.42%)

SAM

Boston Beer

$141.85

-2.45 (-1.70%)

AMSC

AMSC

$7.70

0.3 (4.05%)

SFST

Southern First Bancshares

$33.05

0.25 (0.76%)

BRKL

Brookline Bancorp

$15.95

0.35 (2.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 27

    Apr

  • 28

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 11

    May

  • 16

    May

  • 17

    May

  • 30

    May

  • 31

    May

  • 07

    Jun

  • 12

    Jun

  • 15

    Jun

  • 20

    Jun

  • 21

    Jun

  • 21

    Jun

  • 22

    Jun

  • 22

    Jun

  • 19

    Jul

  • 14

    Aug

  • 27

    Apr

  • 27

    Apr

NWE

NorthWestern

$59.92

-0.23 (-0.38%)

18:13
04/26/17
04/26
18:13
04/26/17
18:13
Earnings
Breaking Earnings news story on NorthWestern »

NorthWestern backs FY17…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 21

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.